Abbott price target lowered to $140 from $145 at BTIG

BTIG analyst Marie Thibault lowered the firm’s price target on Abbott (ABT) to $140 from $145 and keeps a Buy rating on the shares. Shares were down in Thursday trading following the company’s Q4 sales miss and underwhelming 2026 revenue outlook, and the reaction is understandable as nearly all segments underperformed Q4 expectations, the Devices business was not the bright spot it typically is, and the 2026 sales guide was below consensus, the analyst tells investors in a research note. The company is reducing its prices, using promotions, and will release new products this year, but first half is expected to remain weak for Nutrition, BTIG added.